Frequently Asked Questions

Does EasyCheck360 confirm the presence of cancer or indicate the risk of having it?

›
EasyCheck360® detects Circulating Tumour cells in the blood sample of an individual, indicating a higher risk of the presence of cancer. This is a screening test and not a diagnostic test. It highlights the individuals who require further consultation with a physician and additional imaging tests to confirm the findings. 1

Is EasyCheck360 a replacement for mammography or other cancer screening tests?

›
EasyCheck360® is not designed to replace recommended cancer screening methods and should be used alongside them.

Does a 'negative' EasyCheck360 result mean I am currently cancer-free?

›
A negative test means Circulating Tumour Cells (CTCs) were not detected, indicating lower risk of presence of cancer (carcinoma).

How often should I repeat EasyCheck360?

›
Since EasyCheck360® is a non-invasive blood test, it can be done frequently without any drawbacks. However, it is recommended to have the test once every 12 months.

If my EasyCheck360 result is 'positive', what is the next course of action?

›
A positive result indicates that Circulating Tumour Cells were detected, indicating a higher risk of the presence of cancer (carcinoma). Individuals with such findings are advised to undergo a standard of care workup, like imaging in consultation with their physician, to identify if the cancer is present.

Is EasyCheck360 suitable for someone with suspected or noticeable symptoms of cancer?

›
No, individuals with suspected or noticeable symptoms of cancer should promptly consult a medical expert for proper evaluation and guidance.

Can EasyCheck360 be used to monitor cancer recurrence after treatment?

›
No, it is not intended for this purpose.

How does Trublood work?

›
Trublood™ utilises a cutting-edge technique known as immunocytochemistry (ICC) staining to detect Circulating Tumour Cells (CTCs) within the bloodstream. CTCs are cancer cells that break away from the primary tumour and enter the bloodstream, potentially aiding disease spread. This approach not only detects these cells but also differentiates distinct subtypes of CTCs by identifying specific molecular markers, providing critical insights into the cancer's characteristics and potential progression.

Does Trublood™ detect all types of cancer?

›
Trublood™ detects carcinomas, which are cancers that start in cells lining the organs and body surfaces, like the skin, lungs, and colon. It does not detect blood or lymphatic cancer.

Can Trublood™ distinguish between different cancer types, like squamous cell carcinoma and adenocarcinoma?

›
Yes, Trublood™ can often differentiate between cancers originating in glandular cells (like adenocarcinoma) and those in the skin or lining of the lungs (like squamous cell carcinoma).

Can Trublood™ always identify the exact cancer type, including rare ones?

›
Trublood™ can identify common cancer types, such as adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumours, but may not detect some rare subtypes.

Can Trublood™ tell us the tumour's grade?

›
Trublood™ identifies the type of epithelial cancer but does not provide information on the tumour's grade or aggressiveness.

Can Trublood™ be used to track CTC levels over time?

›
Trublood™ is a qualitative test designed for detecting carcinoma in patients with signs or symptoms of cancer. It is not a quantitative test for monitoring by counting CTCs.

Can Trublood™ detect CTCs in early-stage cancer?

›
Yes, Trublood™ has been tested in both early-stage and advanced cancers, with an overall accuracy of 94.6%.

How is Trublood™ different from other cancer screening tests, like CA125 or CA19-9?

›
Trublood™ is not a biochemistry test to detect protein cancer markers; it is a screening test designed for detecting cancer in patients with specific symptoms or organ-related signs.

Can Trublood™ be used for general symptoms of cancer, like weight loss, without a specific organ issue?

›
Trublood™ is validated for cases with a specific organ suspicion, not for non-specific symptoms like weight loss without a particular organ focus.

How is the Trublood™ sample collected?

›
A blood sample is taken from a vein, like routine blood tests, but with specific storage and transport requirements.

How is the sample transported?

›
It is transported in temperature-controlled packaging.

What should I do if Trublood™ is positive?

›
Consult with your doctor for further evaluations.

Do I need a biopsy if Trublood™ is positive?

›
Trublood™ is a highly specific test, but a biopsy may still be recommended based on your doctor’s advice.

What if Trublood™ results are inconclusive?

›
You can repeat the test in a month and consult with your doctor.

Is Trublood™ being used by doctors?

›
Yes, doctors use Trublood™ for the detection of organ-specific cancer cases, especially if a biopsy is challenging.

Can Trublood™ be used for detecting childhood cancers?

›
No, Trublood™ is validated only for adults, 18 years and older.

What advantages does Trublood™ have over a biopsy?

›
Trublood™ is a non-invasive blood test that can detect the presence of cancer and its type without requiring a tissue biopsy.

What are the limitations of Trublood™?

›
Trublood™ cannot detect certain types of cancer like blood cancers, lymphatic cancers, or some rare carcinomas.

Will my doctor treat me based on Trublood™ results?

›
Your doctor may consider Trublood™ results but will factor in other test results as well.

What is Exacta™ analysis?

›
Exacta™ is a detailed analysis that looks at a patient's sample (like tissue, blood, or fluids) to find the best treatment options. It examines DNA, RNA, drug effectiveness, and drug pathways to recommend personalised drug combinations that would most likely work. Treatments are given under the care of your oncologist.

Why is it important to start the treatment right away?

›
Cancer can grow and change quickly, making it harder to treat. Starting treatment immediately helps prevent cancer from becoming resistant to therapies, which may otherwise require a new analysis.

What types of drugs will Exacta™ suggest?

›
The recommendations will only include FDA-approved drugs for cancer or non-cancer conditions. Investigational or experimental drugs will not be included.

Are there follow-up tests to check the therapy's effectiveness?

›
Yes, liquid biopsy allows frequent monitoring of the cancer's status and response to treatment. It can detect signs of recurrence or resistance and help your doctor adjust your treatment plan to improve the quality of life and survival.

Is Pinaka™ a qualitative or quantitative test?

›
Pinaka™ is a qualitative test. It gives a simple result, positive or negative, based on whether certain markers are expressed on the circulating tumour cells or not.

What does a 'negative' Pinaka™ result mean?

›
A 'negative' result means the cancer cells do not show the specific marker being tested.

Can Pinaka™ test therapeutic markers for any cancer type?

›
Pinaka™ is designed to test specific markers based on the approved indications for each type of cancer (e.g., ER, PR, HER2, PDL1, etc.).

How often should I repeat Pinaka™?

›
Since Pinaka™ is a non-invasive blood test, it can be done multiple times over a period to track your progress. Your doctor will decide if and when repeat testing is needed, based on your individual condition and treatment response.

Does Pinaka™ guarantee that I will respond to targeted anti-cancer treatment?

›
Pinaka™ is designed to identify patients who are more likely to benefit from targeted therapies, just like traditional tumour tissue testing. However, your response to treatment depends on various factors, including your health, the specific cancer type, and your immune system.

Can Pinaka™ help monitor cancer recurrence after treatment?

›
Pinaka™ is not designed for monitoring cancer recurrence.

FAQs are available on This Page

›

What is Chemoscale™?

›
Chemoscale™ is a test conducted on live tumour cells to see which drugs or combinations would work more effectively for a cancer patient. This approach avoids the 'trial and error' method, helping patients and doctors make informed treatment decisions based on actual evidence.

Who will benefit from Chemoscale™?

›
Chemoscale™ is beneficial for newly diagnosed patients in choosing the best chemotherapy, for patients with recurring cancer, and for those with solid tumours.

How can Chemoscale™ help?

›
Not all drugs work the same for everyone. Chemoscale™ shows which treatments are likely to be effective before starting, saving time and resources.

How is Chemoscale™ different from other pre-treatment cancer tests?

›
While most tests focus on targeted therapies, Chemoscale™ specifically tests how a patient's cancer cells respond to chemotherapy drugs, allowing for accurate and personalised treatment recommendations.

Will Chemoscale™ work for my type of cancer?

›
Chemoscale™ is suitable for most cancer patients for whom chemotherapy is a treatment option.

How long does it take to get results?

›
Results are available within 12-14 working days after the sample is received.

Why is early detection of cancer's molecular changes important?

›
Cancer cells change quickly, gaining advantages that help them survive and grow. Cancertrack™ monitors these changes in real-time, identifying signs of recurrence, resistance to treatment, or new weaknesses. This information helps doctors adjust treatments promptly.

How often should Cancertrack™ be done?

›
Cancertrack™ is best used at key milestones in cancer treatment, especially during follow-up when imaging shows that the tumour has disappeared, to monitor for recurrence.

What are the limitations of Cancertrack™?

›
Although Cancertrack™ is thorough, individual biological factors can sometimes affect results. However, this impact is usually minimised through repeated testing.

FAQs are not available on for This Page

›

Frequently Asked Questions

Does EasyCheck360 confirm the presence of cancer or indicate the risk of having it?

EasyCheck360® detects Circulating Tumour cells in the blood sample of an individual, indicating a higher risk of the presence of cancer. This is a screening test and not a diagnostic test. It highlights the individuals who require further consultation with a physician and additional imaging tests to confirm the findings. 1

Is EasyCheck360 a replacement for mammography or other cancer screening tests?

EasyCheck360® is not designed to replace recommended cancer screening methods and should be used alongside them.

Does a 'negative' EasyCheck360 result mean I am currently cancer-free?

A negative test means Circulating Tumour Cells (CTCs) were not detected, indicating lower risk of presence of cancer (carcinoma).

How often should I repeat EasyCheck360?

Since EasyCheck360® is a non-invasive blood test, it can be done frequently without any drawbacks. However, it is recommended to have the test once every 12 months.

If my EasyCheck360 result is 'positive', what is the next course of action?

A positive result indicates that Circulating Tumour Cells were detected, indicating a higher risk of the presence of cancer (carcinoma). Individuals with such findings are advised to undergo a standard of care workup, like imaging in consultation with their physician, to identify if the cancer is present.

Is EasyCheck360 suitable for someone with suspected or noticeable symptoms of cancer?

No, individuals with suspected or noticeable symptoms of cancer should promptly consult a medical expert for proper evaluation and guidance.

Can EasyCheck360 be used to monitor cancer recurrence after treatment?

No, it is not intended for this purpose.

How does Trublood work?

Trublood™ utilises a cutting-edge technique known as immunocytochemistry (ICC) staining to detect Circulating Tumour Cells (CTCs) within the bloodstream. CTCs are cancer cells that break away from the primary tumour and enter the bloodstream, potentially aiding disease spread. This approach not only detects these cells but also differentiates distinct subtypes of CTCs by identifying specific molecular markers, providing critical insights into the cancer's characteristics and potential progression.

Does Trublood™ detect all types of cancer?

Trublood™ detects carcinomas, which are cancers that start in cells lining the organs and body surfaces, like the skin, lungs, and colon. It does not detect blood or lymphatic cancer.

Can Trublood™ distinguish between different cancer types, like squamous cell carcinoma and adenocarcinoma?

Yes, Trublood™ can often differentiate between cancers originating in glandular cells (like adenocarcinoma) and those in the skin or lining of the lungs (like squamous cell carcinoma).

Can Trublood™ always identify the exact cancer type, including rare ones?

Trublood™ can identify common cancer types, such as adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumours, but may not detect some rare subtypes.

Can Trublood™ tell us the tumour's grade?

Trublood™ identifies the type of epithelial cancer but does not provide information on the tumour's grade or aggressiveness.

Can Trublood™ be used to track CTC levels over time?

Trublood™ is a qualitative test designed for detecting carcinoma in patients with signs or symptoms of cancer. It is not a quantitative test for monitoring by counting CTCs.

Can Trublood™ detect CTCs in early-stage cancer?

Yes, Trublood™ has been tested in both early-stage and advanced cancers, with an overall accuracy of 94.6%.

How is Trublood™ different from other cancer screening tests, like CA125 or CA19-9?

Trublood™ is not a biochemistry test to detect protein cancer markers; it is a screening test designed for detecting cancer in patients with specific symptoms or organ-related signs.

Can Trublood™ be used for general symptoms of cancer, like weight loss, without a specific organ issue?

Trublood™ is validated for cases with a specific organ suspicion, not for non-specific symptoms like weight loss without a particular organ focus.

How is the Trublood™ sample collected?

A blood sample is taken from a vein, like routine blood tests, but with specific storage and transport requirements.

How is the sample transported?

It is transported in temperature-controlled packaging.

What should I do if Trublood™ is positive?

Consult with your doctor for further evaluations.

Do I need a biopsy if Trublood™ is positive?

Trublood™ is a highly specific test, but a biopsy may still be recommended based on your doctor’s advice.

What if Trublood™ results are inconclusive?

You can repeat the test in a month and consult with your doctor.

Is Trublood™ being used by doctors?

Yes, doctors use Trublood™ for the detection of organ-specific cancer cases, especially if a biopsy is challenging.

Can Trublood™ be used for detecting childhood cancers?

No, Trublood™ is validated only for adults, 18 years and older.

What advantages does Trublood™ have over a biopsy?

Trublood™ is a non-invasive blood test that can detect the presence of cancer and its type without requiring a tissue biopsy.

What are the limitations of Trublood™?

Trublood™ cannot detect certain types of cancer like blood cancers, lymphatic cancers, or some rare carcinomas.

Will my doctor treat me based on Trublood™ results?

Your doctor may consider Trublood™ results but will factor in other test results as well.

What is Exacta™ analysis?

Exacta™ is a detailed analysis that looks at a patient's sample (like tissue, blood, or fluids) to find the best treatment options. It examines DNA, RNA, drug effectiveness, and drug pathways to recommend personalised drug combinations that would most likely work. Treatments are given under the care of your oncologist.

Why is it important to start the treatment right away?

Cancer can grow and change quickly, making it harder to treat. Starting treatment immediately helps prevent cancer from becoming resistant to therapies, which may otherwise require a new analysis.

What types of drugs will Exacta™ suggest?

The recommendations will only include FDA-approved drugs for cancer or non-cancer conditions. Investigational or experimental drugs will not be included.

Are there follow-up tests to check the therapy's effectiveness?

Yes, liquid biopsy allows frequent monitoring of the cancer's status and response to treatment. It can detect signs of recurrence or resistance and help your doctor adjust your treatment plan to improve the quality of life and survival.

Is Pinaka™ a qualitative or quantitative test?

Pinaka™ is a qualitative test. It gives a simple result, positive or negative, based on whether certain markers are expressed on the circulating tumour cells or not.

What does a 'negative' Pinaka™ result mean?

A 'negative' result means the cancer cells do not show the specific marker being tested.

Can Pinaka™ test therapeutic markers for any cancer type?

Pinaka™ is designed to test specific markers based on the approved indications for each type of cancer (e.g., ER, PR, HER2, PDL1, etc.).

How often should I repeat Pinaka™?

Since Pinaka™ is a non-invasive blood test, it can be done multiple times over a period to track your progress. Your doctor will decide if and when repeat testing is needed, based on your individual condition and treatment response.

Does Pinaka™ guarantee that I will respond to targeted anti-cancer treatment?

Pinaka™ is designed to identify patients who are more likely to benefit from targeted therapies, just like traditional tumour tissue testing. However, your response to treatment depends on various factors, including your health, the specific cancer type, and your immune system.

Can Pinaka™ help monitor cancer recurrence after treatment?

Pinaka™ is not designed for monitoring cancer recurrence.

FAQs are available on This Page

What is Chemoscale™?

Chemoscale™ is a test conducted on live tumour cells to see which drugs or combinations would work more effectively for a cancer patient. This approach avoids the 'trial and error' method, helping patients and doctors make informed treatment decisions based on actual evidence.

Who will benefit from Chemoscale™?

Chemoscale™ is beneficial for newly diagnosed patients in choosing the best chemotherapy, for patients with recurring cancer, and for those with solid tumours.

How can Chemoscale™ help?

Not all drugs work the same for everyone. Chemoscale™ shows which treatments are likely to be effective before starting, saving time and resources.

How is Chemoscale™ different from other pre-treatment cancer tests?

While most tests focus on targeted therapies, Chemoscale™ specifically tests how a patient's cancer cells respond to chemotherapy drugs, allowing for accurate and personalised treatment recommendations.

Will Chemoscale™ work for my type of cancer?

Chemoscale™ is suitable for most cancer patients for whom chemotherapy is a treatment option.

How long does it take to get results?

Results are available within 12-14 working days after the sample is received.

Why is early detection of cancer's molecular changes important?

Cancer cells change quickly, gaining advantages that help them survive and grow. Cancertrack™ monitors these changes in real-time, identifying signs of recurrence, resistance to treatment, or new weaknesses. This information helps doctors adjust treatments promptly.

How often should Cancertrack™ be done?

Cancertrack™ is best used at key milestones in cancer treatment, especially during follow-up when imaging shows that the tumour has disappeared, to monitor for recurrence.

What are the limitations of Cancertrack™?

Although Cancertrack™ is thorough, individual biological factors can sometimes affect results. However, this impact is usually minimised through repeated testing.

FAQs are not available on for This Page

Got An Enquiry?
Contact Us.